These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 29799326)

  • 1. The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
    Bly CA; Molife C; Brown J; Tawney MK; Carter GC; Cinfio FN; Klein RW
    J Manag Care Spec Pharm; 2018 Jun; 24(6):534-543. PubMed ID: 29799326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan.
    Graham J; Earnshaw S; Burslem K; Lim J
    J Manag Care Spec Pharm; 2018 Jun; 24(6):544-553. PubMed ID: 29799327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 4. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
    Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
    Bloudek L; Roy A; Kish JK; Siegel DS; Jagannath S; Globe D; Orloski L; Kuriakose ET
    J Manag Care Spec Pharm; 2016 Aug; 22(8):991-1002. PubMed ID: 27459662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer.
    Flannery K; Drea E; Hudspeth L; Corman S; Gao X; Xue M; Miao R
    J Manag Care Spec Pharm; 2017 Apr; 23(4):416-426. PubMed ID: 28345444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer.
    Danese MD; Reyes C; Northridge K; Lubeck D; Lin CY; O'Connor P
    Clin Ther; 2008 Apr; 30(4):775-84. PubMed ID: 18498925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan.
    Ramsey SD; Clarke L; Kamath TV; Lubeck D
    J Manag Care Pharm; 2006; 12(6):472-8. PubMed ID: 16925455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.
    Sorensen S; Ellis L; Wu Y; Hutchins V; Linnehan JE; Senbetta M
    J Manag Care Pharm; 2013; 19(9):799-808. PubMed ID: 24156649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer.
    Appukkuttan S; Farej R; Miles L; Purser M; Wen L
    J Manag Care Spec Pharm; 2021 Feb; 27(2):166-174. PubMed ID: 33141615
    [No Abstract]   [Full Text] [Related]  

  • 11. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
    Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng HF
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1567-1575. PubMed ID: 33043821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States.
    Borer JS; Kansal AR; Dorman ED; Krotneva S; Zheng Y; Patel HK; Tavazzi L; Komajda M; Ford I; Böhm M; Kielhorn A
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1064-71. PubMed ID: 27579829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    Schultz NM; O'Day K; Sugarman R; Ramaswamy K
    J Manag Care Spec Pharm; 2020 Apr; 26(4):538-549. PubMed ID: 32020841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective.
    Stellato D; Gerbasi ME; Ndife B; Ghate SR; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1227-1237. PubMed ID: 31663466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer.
    Ho J; Zhang L; Todorova L; Whillans F; Corey-Lisle P; Yuan Y
    J Manag Care Pharm; 2009; 15(6):467-75. PubMed ID: 19610679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with
    Bhandari NR; Gilligan AM; Myers J; Ale-Ali A; Smolen L
    J Med Econ; 2024; 27(1):348-358. PubMed ID: 38334069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study.
    Park K; Cho EK; Bello M; Ahn MJ; Thongprasert S; Song EK; Soldatenkova V; Depenbrock H; Puri T; Orlando M
    Cancer Res Treat; 2017 Oct; 49(4):937-946. PubMed ID: 28111429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
    Bui CN; O'Day K; Flanders S; Oestreicher N; Francis P; Posta L; Popelar B; Tang H; Balk M
    J Manag Care Spec Pharm; 2016 Feb; 22(2):163-70. PubMed ID: 27015255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
    Carlson JJ; Wong WB; Veenstra DL; Reyes C
    J Med Econ; 2011; 14(2):159-66. PubMed ID: 21288059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis.
    Vadagam P; Kamal KM; Covvey JR; Giannetti V; Mukherjee K
    J Manag Care Spec Pharm; 2018 Oct; 24(10):987-997. PubMed ID: 30247102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.